CA
NZ
UK
AU
IND
US
Operating expenses rose to $30.3 million from $25.4 million. Other income, net, increased to $4.1 million from $3.0 million, mainly on interest earned on IPO proceeds.
The San Jose medical device company develops procedural solutions for compromised bone, with products centered on the sacroiliac joint and the spinopelvic region. It has supported physicians in more than 160,000 procedures since 2009.
Sinda is an exploration-stage company that holds five contiguousMiningconcessions in Guanajuato, Mexico, covering a high-grade silver and gold discovery. It has no revenue, and its filing reports only operating expenses, which rose to $17.0 million from $2.7 million.
Rental income dropped to $4.5 million from $24.2 million after shopping center sales, while fee and other income rose to $4.1 million from $2.9 million. The fees come from services provided to the property owner it spun off in October 2024.
Syndax is a commercial-stage biopharmaceutical company focused on cancer. Revuforj is a menin inhibitor for relapsed or refractory acute leukemia with KMT2A or NPM1 alterations, while Niktimvo treats chronic graft-versus-host disease and is commercialized with a partner that books the sales.
The company develops at-home pneumatic compression therapy for lymphedema, including the Flexitouch and Nimbl systems, and sells the AffloVest airway clearance device. Lymphedema revenue increased $9.5 million to $81.8 million, a 13.1% gain and about 11% higher than the second quarter.
The company provides aviation aftermarket services, including repair and overhaul of auxiliary power units (APUs) and heat exchangers, as well as trading, leasing and distribution of aircraft parts.Operating Incomereached $9.0 million, or 16.3% of revenue, versus $5.3 million, or 11.4%.
Diagnostics revenue was $303.5 million, up from $252.9 million. Management said oncology revenue grew 28% to about $173 million onVolumegrowth of 32%, while hereditary testing contributed about $111 million.
Orders grew 9.5%, andBacklogwas about $118 million, which management said supports fourth quarter sales. Robotics sales reached about $37.3 million, and year-to-date robotics sales already exceed the full-year 2025 total. The company recently launched the P1 autonomous vacuum to reach more customer applications and …
The company is an energy services and solutions provider operating on six continents, with calcium chloride, completion fluids and produced water management among its offerings. It reports two segments, Completion Fluids and Products and Water and Flowback Services. Net income attributable to stockholders was …
Please wait processing your request...